QC
CORT icon

Quantessence Capital’s Corcept Therapeutics CORT Stock Holding History

Quantessence Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-33,966
Closed -$2.49M – 206
2025
Q2 		$2.49M Buy
+33,966
New +$2.46M 0.73% 30

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quantessence Capital's CORT Position: Q3 2025 in Review

Quantessence Capital sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 33,966 shares — an estimated $2.49M sold.

Quantessence Capital first reported a position in CORT in Q2 2025 and held it in 1 quarter. The position peaked at $2.49M in Q2 2025. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Quantessence Capital reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Quantessence Capital sold 33,966 Corcept Therapeutics shares in Q3 2025, an estimated $2.49M.
  • Quantessence Capital first reported a position in Corcept Therapeutics in Q2 2025 and held it in 1 quarter.
  • Quantessence Capital's Corcept Therapeutics position peaked at $2.49M in Q2 2025.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.